Seizure Activity and Off-Label Use of Tiagabine
| Autor: | Judith A. Racoosin, Cindy Kortepeter, Charlene M. Flowers |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Drug Pediatrics medicine.medical_specialty Adolescent Tiagabine media_common.quotation_subject Nipecotic Acids Status epilepticus Off-label use Food and drug administration Seizures medicine Humans Drug Interactions Seizure activity Drug Approval Drug Labeling media_common partial seizures business.industry General Medicine medicine.disease Anesthesia Adjunctive treatment Anticonvulsants Epilepsies Partial medicine.symptom business medicine.drug |
| Zdroj: | New England Journal of Medicine. 354:773-774 |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejmc055301 |
| Popis: | To the Editor: Thirty-one case reports of new-onset seizures associated with off-label use of tiagabine (Gabitril) have prompted the addition of a boldface warning to the product label.1 (Tiagabine is approved by the Food and Drug Administration [FDA] solely for adjunctive treatment of partial seizures in adults and children 12 years of age and older.) The mean duration of exposure to tiagabine before the occurrence of a seizure was three to four months, but in some cases seizures occurred within days after the initiation of the drug or an increase in the dose. Although there were no deaths, status epilepticus . . . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|